An experienced legal, regulatory and compliance department leader, Patricia I. Kovacevic’s career comprises leading senior legal and regulatory positions with FDA-regulated multinationals, including Philip Morris International and Lorillard, as well as partner roles with premier global law firms. At present she is General Counsel and Head of External Affairs for Andina Gold Corp (corporate name change to Cryomass Technologies Inc pending), a U.S. listed company providing adjacent services to the cannabis industry, which has recently acquired patented technology (the CryomMass Refinement System) to fully separate trichomes from biomass.
Her expertise includes senior management roles and leading multinational, cross-disciplinary teams, with focus on corporate law, FDA and EU regulatory, compliance, M&A, US and global food, drug, nicotine and consumer goods regulation, cannabis/CBD regulation, external affairs and the legal framework applicable to marketing, media communications, investigations, FCPA, trade sanctions, privacy, intellectual property, product development and launch. She also led cross-disciplinary teams engaged in scientific research efforts. Kovacevic served on various trade association bodies and conference advisory boards. She authored several articles on nicotine regulation, co-authored an academic treatise, “The Regulation of E-Cigarettes”, as well as various other papers, and is often invited as a keynote speaker or panelist before global conferences and government agencies public hearings. Kovacevic is an attorney admitted to practice in New York, before the U.S. Tax Court, before the U.S. Court of International Trade and before the Supreme Court of the United States. She holds a Juris Doctor (doctor of law) degree from Columbia Law School in New York and completed the Harvard Business School “Corporate Leader” executive education program. Kovacevic speaks several languages fluently, including French, Italian, Spanish, Romanian and Croatian.
Dr. Sarah Baxter-Wright serves as the Vice President, US Life Sciences for Reynolds American (Reynolds), a wholly owned subsidiary of British American Tobacco. In this role, she leads a team responsible for analytical testing, clinical studies, population health, consumer behavior, and statistics as part of Scientific Research & Development.
Dr. Baxter holds a Ph.D. in Biochemistry from Vanderbilt University, Nashville, TN, with training in biomarkers and systems biology, focusing on proteomics and metabolomics. Since joining Reynolds in 2016, Dr. Baxter has held positions including Senior Director of Clinical Studies, Vice President-Scientific and Regulatory Affairs, Head of Analytical and Preclinical Sciences, and Head of Clinical and Behavioral Sciences. Prior to joining Reynolds, Dr. Baxter held scientific research positions in several organizations focusing on cancer research, agriculture, health and nutrition, pharmaceutical testing, and biodefense.
Brandon is a drug developer with deep oncology and immunology experience. He has a particular focus on how CROs can support in expanding the capabilities of small biotech companies. In his current role, he oversees and develops high performance teams to deliver client clinical development portfolios. Prior to his time with ICON, Brandon led global oncology and immuno-oncology programmes in the biotech and CRO sectors. He received his Masters and Undergraduate degrees from the University of Virginia, US.
Elizabeth has been an expert in the cold chain life sciences healthcare industry for over 10 years. Her experience spans operations, account management, and business development. She established herself as a subject matter expert on active and passive packaging, and collaborated on education and a solutions portfolio for cold chain pharmaceutical logistics.
As part of the DHL Life Sciences & Healthcare sector, Elizabeth drives the cross-divisional development of clinical trials logistics offering. She sits at the head of the marketing work stream, and is a primary stakeholder for marketing collateral and content. She is also a primary contributor to the commercial aspect of the company’s COVID-19 vaccine distribution strategy and public sector initiatives.
